November 2016November 2016
New Indications
Gazyva (obinutuzumab) in combination with bendamustine, followed by Gazyva maintenance, is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond to, or who progressed during or up to 6 months after treatment with rituximab or a rituximab containing regimen.
Humira (adalimumab (rch)) is now indicated for the treatment of enthesitis related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy. Humira is now also indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.
Targin (oxycodone hydrochloride; naloxone hydrochloride) is now also indicated as second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au